Lonza Plans $200-Million Investment in China for APIs and Intermediates
The custom manufacturer Lonza Group (Basel, Switzerland) will invest $200 million in Nansha Guangzhou, China, for production of active pharmaceutical ingredients (APIs) and intermediates.
The custom manufacturer Lonza Group (Basel, Switzerland, www.lonza.com) will invest $200 million in Nansha Guangzhou, China, for the production of active pharmaceutical ingredients (APIs) and intermediates.
The investment plan will occur in phases over a 3–5-year period. Lonza's plan design includes building a multipurpose API and intermediates plant complex with large- and pilot-scale production capabilities. The company also recently opened a new R&D center for intermediates and APIs in Nansha.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
